期刊名称：CANCER BIOLOGY & THERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Cancer Biology & Therapy is a peer-reviewed journal which publishes original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We include timely reviews covering the broad scope of the journal. CB&T also publishes Commentaries, Bedside-to Bench Reports, Research Philosophy and meeting reports. The goal is to foster communication and a rapid exchange of information through expedient publication of important results using traditional, as well as electronic, formats. The journal and the outstanding Editorial Board strive to maintain the highest standards for excellence in all activities to generate a valuable resource. Accepted manuscripts are posted to the website rapidly.
Instructions to Authors
Articles and Papers
Reviews will be brief (2,000 to 4,000 words). These will generally be invited, but unsolicited proposals for reviews will be considered. Research papers should be no longer than 4,000 words. Assistance in creating artwork can be provided by Landes Bioscience on a limited basis if necessary. Meeting reports will be invited. They are to be 1,000 to 2,000 words. Other feature articles (including special forums, commentaries, columns on ethics, and technology) should be 1000 to 2000 words in length.
For all submissions, please indicate one or two areas of the work’s focus, as reflected by the interest of the journal and the expertise of the Associate Editors (Receptor Signaling, Molecular Therapy, Signal Transduction, Cancer Genomics, Animal Models, DNA Replication, Radiobiology, Surgical Oncology, DNA/RNA Therapies, Tumor Hypoxia, Cell Cycle Control, DNA Methylation, Tumor Immunology, Cancer Pathogenesis, Translocations, Tumor Virology, Tumor Metastasis, Hereditary Cancer, Transcription/Repair, Cancer Transcriptomes, Research Philosophy, Apoptosis, Gene Therapy, Clinical Trials, Breast Biology, Cancer Biology, Tumor Imaging, Angiogenesis).
|
Peer Review
Each contribution is rigorously vetted by at least two expert reviewers who are either members of the Editorial Board or are recruited by Board members.
For original articles or short reports, reviewers will be asked to comment on the following aspects of the submitted manuscripts:
significance to the field;
study design;
quality of data;
quality of controls;
whether conclusions are justified;
whether the effects are meaningful;
whether the study is described clearly;
and to comment on the novelty of the work.
If the reviewers believe the paper is potentially acceptable but could be improved, specific suggestions will be made for improvement.
Final acceptance of all submitted manuscripts is a decision made by the Editor-in-Chief in consultation with the Editorial Board and reviewers. If a manuscript is believed to not meet the standards of the journal or is otherwise lacking in scientific rigor or contains major deficiencies, the reviewers will attempt to provide constructive criticism to assist the authors in ultimately improving their work for publication, here or elsewhere. Manuscripts not invited for resubmission will not be reconsidered.
If a manuscript receives favorable reviews but is not accepted outright following the initial review, it may be invited for reconsideration with the expectation that the authors will fully address the reviewer’s criticisms. Resubmitted manuscripts with major revisions will be sent back for peer review.
Accepted papers will be rapidly posted to the journal website as Papers-in-Press. |
General Manuscript Submission
|
|
Please direct questions regarding submission to: |
|
Wafik S. El-Deiry, M.D., Ph.D.
Editor-in-Chief, Cancer Biology and Therapy
University of Pennsylvania
415 Curie Blvd. CRB 437A
Philadelphia, PA 19104
Tel.: 215.898.9015
Fax: 215.573.9139
wafik@mail.med.upenn.edu |
| |
| Please submit manuscripts (hardcopy and disk) to: |
|
Kim Mitchell
Landes Bioscience
810 S. Church St.
Georgetown, TX 78626
Tel.: 512.863.7762
Fax: 512.863.0081
Email: kimm@landesbioscience.com | |
|
To save time and expense, authors may choose to initially submit their manuscripts via email to kimm@landesbioscience.com and wafik@mail.med.upenn.edu as a PDF and as a Microsoft Word file, which will be rapidly posted to the CB&T peer-review website. Accepted PDF files will be posted as "Papers-in-Press." Upon acceptance, authors are requested to refer to the "Production Guidelines" and the "Manuscript Submission Form" for disk and artwork submission requirements for the print version. These will be forwarded to the authors following manuscript acceptance in order to prepare high quality reproductions.
If you submit your manuscript electronically please check to ensure that it was received. While the vast majority of submissions via email are received with no problem and the process proceeds normally, from time to time emails are lost or may even bounce back many months later. We strive at CB&T to immediately contact authors to confirm receipt of submissions and attempt to complete the review process within 2-3 weeks.
If you have any further questions regarding the email submission process, please do not hesitate to contact Kim Mitchell
Email: kimm@landesbioscience.com; Phone 512.863.7762 |
|
Please make sure to notifiy the Editor-in-Chief, Dr. El-Deiry, once a manuscript has been submitted. |
Pathway 2 for Manuscript Submission
Authors may also submit a manuscript to CB&T requesting that a specific Associate Editor oversee the review for consideration by the journal. If an author chooses this mechanism, the following conditions apply.
1. The senior author will have previously contacted the Associate Editor and obtained their agreement to oversee the review of the manuscript.
2. The manuscript is in the area of expertise of the Associate Editor.
3. Copies of the manuscript are otherwise submitted to the journal using the required normal procedure with correspondence to the Editor-in-Chief explaining what is being done. This is important for tracking manuscripts under review and so as not to overburden Associate Editors with too many manuscripts. In such situations, a manuscript may be sent to others for review.
4. The final decision regarding manuscript acceptance will be made by the Editor-in-Chief in consultation with the Associate Editor following review of the manuscript. The journal reserves the right to obtain additional reviews for any manuscript under consideration.
Policy of Cancer Biology and Therapy on commercial or pharmaceutic contributors or work funded by pharmaceutical companies
Original research manuscripts or other categories of submission are peer-reviewed and institutional affiliation as listed by authors is known to the journal editors and scientific peer reviewers. Authors are invited to contribute reviews based on the interest in their work and particular topic of relevance to the journal. Authors are expected to disclose their institutional affiliations as well as sources of funding for their submitted work. The journal, Editors, and peer reviewers make every effort to avoid conflicts of interest. The standard peer review process requires reviewers to recuse themselves in cases of real or even perceived conflict of interest. Pharmaceutical affiliation is not in and of itself (nor should it be) an obstacle to publication in Cancer Biology and Therapy. In fact, because of the high interest of this journal in translational research and new drug development for cancer, such efforts by pharmaceutical colleagues are welcome. Funding from pharmaceutical companies for research is not in and of itself problematic because it is assumed that authors have integrity and perform research according to ethical practices. The journal and Editors strive to include balanced points of view, alternative models, strategies, drugs, targets, and mechanisms and invite members of the scientific community to take an active role in this process. Publication in Cancer Biology and Therapy does not constitute an endorsement by the journal or the Editors of any product, drug, specific target or institution.
Editorial Guidelines
Text should be double-spaced, with page numbers throughout.
Language and Nomenclature
Abbreviations and acronyms should be defined the first time they are used, and a list of all abbreviations should be provided. American spellings are preferred.
Organization
Title Page ?Please include names and insitutional affiliation of all authors, along with their academic degrees. Galley proofs will be sent to the corresponding author, so please indicate clearly who this is, along with his or her address, telephone and fax numbers, and email address. Acknowledgements should be kept to a minimum.
Abstract ?A separate abstract page should contain the following: (1) Author’s surnames and initials, (2) Title of manuscript, (3) Title of Journal (4) The word abstract followed by a summary of the article, (not to exceed 200 words), (5) 3-10 key words according to Index Medicus, (6) 5-10 definitions of key terms or phrases used throughout the article, (7) a 5-7 bulleted summary (main points) of the article.
Introduction ?Present the background briefly, but do not review the subject extensively. Give only pertinent references. If a research paper, state the specific questions you want to answer.
Reviews
Although reviews should be recognized as scholarly by specialists in the field being covered, they also should be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose. Please avoid excessive jargon and technical detail. Reviews should capture the broad developments and implications of recent work. The opening paragraph should make clear the general thrust of the review and provide a clear sense of why the review is now particularly appropriate. The concluding paragraph should provide the reader with an idea of how the field may develop or future problems to be overcome, but should not summarize the article. To ensure that a Review is likely to be accessible to as many readers as possible, it may be useful to ask a colleague from another discipline to read the review before submitting it. Reviews are limited to approximately 2,000-4,000 words and should be well illustrated. If very technical concerns are essential to the Review, these should be presented in a separate box.
Meeting Reports
Authors are encouraged to contact the Journal with proposals for meeting reports. Please contact the meeting organizers to verify that reports will be permitted. In the case of Gordon Research Conferences, reports are not allowed to be publisehd under any circumstances. In the case of other scientific meetings, please ensure that permission is given by any presenter whose unpublished work will be mentioned, along with a notation in the text (cited with permission from Dr. Nobel Laureate, Dr. Nobel Laureate, M.D., personal communication, or Dr. Nobel Laureate, Jr., manuscript in preparation, submitted, in revision, or in press).
Bedside-to-Bench Reports
These consist of one or more case reports, followed by a thorough and up-to-date discussion of the molecular biology of the disease. These reports should include an abstract, a brief introduction, and a clinical case report, followed by a discussion of Clinical Features, Pathology, Radiology, Therapy, and Molecular Features. The total report should be kept under 4,000 words, and the Molecular Features should comprise about one-half to two-thirds of the report. The goal of this section is to provide clinicians witha perspecive of the molecular aspects, and the basic scientists with a perspective of the clinical aspects. This represents one format through which CB&T will impart translational knowledge.
Research Papers
Patients and Methods / Materials and Methods ?Describe selection of patients or experimental animals, including controls. Do not use patients?names or hospital numbers. Identify methods, apparatus (manufacturer’s name and address), and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods. Evaluate their advantages and limitations. Identify drugs and chemicals, including generic name, dosage, and route(s) of administration.
Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.
Results ?Present results in logical sequence in tables and illustrations. In the text, explain, emphasize or summarize the most important observations. Units of measurement should be expressed in accordance with Systeme International d’Unites (SI Units).
Discussion ?Do not repeat in detail data given in the Results section. Emphasize the new and important aspects of the study. Relate observations to other relevant studies. On the basis of your findings (and others?, discuss possible implications/conclusions. When stating a new hypothesis, clearly label it as such.
Tables ?Tables should be numbered consecutively with Arabic numerals. Type each table on a separate sheet, with self-explanatory labels.
References
References for review articles are limited to 60. For research papers, please limit references to 75. Important references should be annotated. References in the text are numbered consecutively as superscripts beginning with number 1. Punctuation always precedes the superscript.
The list of references should be numbered consecutively according to the first time mentioned within the article. Our preferred style for reference listings is "Vancouver," omitting periods after journal abbreviations. Abbreviate journal names according to the style used in Index Medicus or a comparable source. Spell out foreign or less commonly known journal names.
Example:
...according to Jones.1
not …Jones1.
...noted by Smith et al.1
not ...Smith et al (1).
When referring the reader to specific references as part of a sentence, cite as:
Example:
For a review see refs. 20-25.
not ...For a review see 20-25
Journals: [Author’s last name] [Author’s initials], [Other authors?last names followed by their initials]. [Title of article with only first word capitalized]. [Journal’s standard abbreviated name] [Year]; [Volume (number)]:[Inclusive pages].
Only the first six authors are listed. If there are more than six authors, the first six names are followed by "et al." Initials and abbreviations are not followed by periods.
-Unpublished data and personal communications are not listed as references but rather appear in parentheses in the text.
Example:
up to six authors:
1. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-468.
more than six authors:
1. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM et al. Nucleotide substitution in the ectodomain of trail recepto dr4 is associated with lung cancer and head and neck cancer.
Books: [Author’s last name] [Author’s initials], [Other authors?last names followed by initials]. [Chapter title]. In: [Editor’s last name] [Editor’s initials], ed(s). [Book Title]. [Number of edition]. [City]:[Publisher], [Year]:[Inclusive pages].
Example:
1.Ozoren N, El-Diery WS. Introduction to cancer genes and growth control. In: Ehrlic M, ed. DNA Alterations in Cancer: Genetic and Epigenetic Changes. Natick, MA: Eaton Publishing, 2000:3-43.
Production Guidelines
We are an entirely Mac-based office. However, most IBM-compatible or Macintosh word processing programs are acceptable.
How to prepare text files
Our preferred word processing program is Microsoft Word. Please save as version 6.0 (Please no "Fast-Save" format).
Article text files should be submitted on a 3.5 inch, high-density computer disk, a zip disk, or a CD. Save tables and figures in a document separate from text. Figure captions, however, can be at the end of the review as text. There is no need to make a unique file for captions. Tables will be reformatted during production, and therefore they need only be minimally formatted in your text file. Include printouts of tables with the manuscript.
How to prepare figures, illustrations & photos
When art is provided on disk, a single hard copy should be included to verify the illustration. PLEASE DO NOT EMBED GRAPHICS WITHIN YOUR TEXT DOCUMENT. Compatible computer graphics programs are Adobe Illustrator, Adobe Photoshop and Microsoft PowerPoint. Figures and illustrations may be provided by authors as hard copy as well. Hard copies should be high-quality prints, with two copies of each illustration submitted. Figures will be reformatted by a graphic designer not a medical scientist so an enclosed figure description for complex illustrations will be appreciated and result in an improved quality. Send only original artwork, no photo-copies. Photography will be published only if the quality is reproducible. Please submit high-quality prints or slides for best quality.
All artwork should be labeled with the author’s name, the figure number and the correct orientation of the figure, but be sure that labeling is clear of the image. Do not put the label directly behind the image. Do not write directly on the back of the photograph or on the label after it has been applied. Indicate any special cropping on a photocopy of the figure.
When illustrations are reproduced from other sources, acknowledge the copyright holder at the end of the figure legend or as a footnote to tables. Do not use superscripted reference numbers in lieu of a full credit line.
Label disks with author name(s), article title, files enclosed, and please name your file [main author’s surname] or a keyword from the title.
|
There will be a solution if you cannot submit your manuscript and/or figures in the desired format.
Please get in touch with us before you send your work if you have problems or questions.
A phone call saves everyone time. |
Page Proofs
Page proofs should be returned within two working days, preferably by fax or overnight mail. Corrections should be marked on the actual proof and provided in a numbered list. Lengthy additions should be avoided, but where necessary should be provided on disk with written instructions.
Offprints and Reprints
Offprints can be ordered before press time. Reprints can be ordered later, at additional cost. Prices depend upon the quantity ordered and length of article.
Editorial Board
|
Editorial Board |
Associate Editors | |
| Robert T. Abraham |
Avi Ashkenazi, Ph.D.
Genentech ¡ª San Francisco, CA
(Receptor Signaling)
webpage |
Joseph R. Bertino, M.D.
Cancer Institute of New Jersey¡ªNew Brunswick, NJ
(Molecular Therapy)
webpage |
Mikhail V. Blagosklonny, M.D., Ph.D.
New York Medical College¡ªHawthorne, NY
(Signal Transduction)
publications |
Carlos Caldas, M.D., F.A.C.P
Cambridge University ¡ª Cambridge, UK
(Cancer Genomics)
webpage |
Lewis A. Chodosh, M.D., Ph.D.
University of Pennsylvania ¡ª Philadelphia, PA
(Animal Models)
webpage |
Anindya Dutta, M.D., Ph.D.
Harvard University ¡ª Boston, MA
(DNA Replication)
webpage |
Albert J. Fornace, Jr., M.D.
National Institutes of Health ¡ª Bethesda, MD
(Radiobiology)
webpage |
Douglas Fraker, M.D.
University of Pennsylvania ¡ª Philadelphia, PA
(Surgical Oncology)
webpage |
Alan M. Gewirtz, M.D.
Univeristy of Pennsylvania ¡ª Philadelphia, PA
(DNA/RNA Therapies)
webpage |
Amato J. Giaccia, Ph.D.
Stanford University ¡ª Stanford, CA
(Tumor Hypoxia)
webpage |
Antonio Giordano, M.D., Ph.D.
Sbarro Institute at Temple University¡ª Philadelphia, PA
(Cell Cycle Control)
webpage |
James G. Herman, M.D.
Johns Hopkins University ¡ª Baltimore, MD
(DNA Methylation)
webpage |
Carl H. June, M.D.
University of Pennsylvania ¡ª Philadelphia, PA
(Tumor Immunology)
webpage |
Scott E. Kern, M.D.
Johns Hopkins University ¡ª Baltimore, MD
(Cancer Pathogenesis)
webpage |
Jonathan Licht, M.D.
Mt. Sinai Medical School ¡ª New York, NY
(Translocations)
webpage |
Karl Munger, Ph.D.
Harvard University ¡ª Boston, MA
(Tumor Virology)
webpage |
Ruth Muschel, M.D., Ph.D.
University of Pennsylvania ¡ª Philadelphia, PA
(Tumor Metastasis )
webpage |
Ramon Parsons, M.D., Ph.D.
Columbia University ¡ª New York, NY
(Hereditary Cancer)
webpage |
Jeffrey Parvin, M.D., Ph.D.
Harvard University ¡ª Boston, MA
(Transcription/Repair)
webpage |
Kornelia Polyak, M.D., Ph.D.
Harvard University ¡ª Boston, MA
(Cancer Transcriptomes)
webpage |
Vivek Rangnekar, Ph.D.
University of Kentucky ¡ª Lexington, KY
(Research Philosophy)
webpage |
John C. Reed, M.D., Ph.D.
The Burnham Institute ¡ª La Jolla, CA
(Apoptosis)
webpage |
Jack A. Roth, M.D.
MDACC ¡ª Houston, TX
(Gene Therapy)
webpage |
Eric K. Rowinsky, M.D.
CTRC ¡ª San Antonio, TX
(Clinical Trials)
webpage |
Joan Ruderman, Ph.D.
Harvard Medical School ¡ª Boston, MA
(Mitosis)
webpage |
Saraswati Sukumar, Ph.D.
Johns Hopkins University ¡ª Baltimore, MD
(Breast Biology)
webpage |
Bert Vogelstein, M.D.
HHMI, Johns Hopkins Kimmel Cancer Center ¡ª Baltimore, MD
(Cancer Therapy)
webpage |
Robert Weinberg, Ph.D.
Massachusetts Institute of Technology ¡ª Cambridge, MA
(Cancer Biology)
webpage |
Ralph Weissleder, M.D., Ph.D.
Harvard University ¡ª Boston, MA
(Tumor Imaging)
webpage |
Bruce Robert Zetter, Ph.D.
Harvard University ¡ª Boston, MA
(Angiogenesis)
webpage |
|
| Peter Adams |
| Alex Almasan |
| Emad S. Alnemri |
| Dario C. Altieri |
| Wadih Arap |
| Jeffrey M. Arbeit |
| Carlos L. Arteaga |
| Debabrata Banerjee |
| Menashe Bar-Eli |
| J. Carl Barrett |
| Stephen B. Baylin |
| Dorothea Becker |
| Atul Bedi |
| Alfonso Bellacosa |
| Robert Benezra |
| Laura E. Benjamin |
| Eric J. Bernhard |
| Kapil Bhalla |
| Zaver M. Bhujwalla |
| Manoop S. Bhutani |
| David A. Boothman |
| Rainer K. Brachmann |
| James D. Brenton |
| Peter C. Brooks |
| J. Martin Brown |
| Dmitry Bulavin |
| Paul Cairns |
| Brian R. Calvi |
| Christine Canman |
| Michele Carbone |
| Lucio H Castilla |
| Ann F. Chambers |
| Navdeep S. Chandel |
| Preet M. Chaudhary |
| David A. Cheresh |
|
Pinchas Cohen |
| Suzanne D. Conzen |
| Kenneth Cowan |
| David T. Curiel |
| Douglas C. Dean |
| Chuxia Deng |
| Paul Dent |
| Michael Detmar |
| Quinn Deveraux |
| J. Allan Diehl |
| Paul W. Doetsch |
| Bruce J. Dolnick |
| Larry Donehower |
| Dorraya El-Ashry |
| Abdel. G. Elkahloun |
| Gregory H. Enders |
| Carolyn A. Felix |
| William D. Figg |
| Richard Fishel |
| Antonio T. Fojo |
| Joseph A. Fontana |
| Paul B. Fisher |
| Thomas F. Franke |
| Leonard P. Freedman |
| Alan D. Friedman |
| Steven Frisch |
| Giampietro Gasparini |
| Donna L. George |
| Peter M. Glazer |
| L. Michael Glode |
| Michael G. Goggins |
| Gregory J. Gores |
| Joe W. Gray |
| Mark I. Greene |
| Andrei Gudkov |
| Daniel Haber |
| Nagy A. Habib |
| William C. Hahn |
| Michinari Hamaguchi |
| William J. Harrington, Jr. |
| Mary J.C. Hendrix |
| Meenhard Herlyn, D.V.M |
| Lynn R. Hlatky |
| Shawn E. Holt |
| Mien-Chie Hung |
| Patrick Hwu |
| George Iliakis |
| Luisa Iruela-Arispe |
| Jean-Pierre Issa |
| Elizabeth M. Jaffee |
| Olli-P. Kallioniemi |
| Khandan Keyomarsi |
| David Kirn |
| Kamel Khalili |
| Cameron J. Koch |
| H. Phillip Koeffler |
| Richard N. Kolesnick |
| Keith Laderoute |
| David S. Latchman |
| Dr. Yuri Lazebnik |
| Fredrick S. Leach |
| Christoph Lengauer |
| Hyam I. Levitsky |
| Reuben Lotan |
| David N. Louis |
| Carl Maki |
| James J. Manfredi |
| W. Stratford May, Jr. |
| Andrea I. McClatchey |
| David J. McC |
| Keith R. McCrae |
| James A. McCubrey |
| Timothy J. McDonnell |
| Gerry Melino |
| Neal J. Meropol |
| Matthew Meyerson |
| John D. Minna |
| Alvaro N.A. Monteiro |
| William F. Morgan |
| Marsha A. Moses |
| Mary Ellen Moynahan |
| James J. Mule |
| Maureen E. Murphy |
| Mark A. Nelson |
| William G. Nelson, V |
| John Nemunaitis |
| Yoshiro Niitsu |
| Toru Ouchi |
| Renata Pasqualini |
| Warren S. Pear |
| Kenneth J. Pienta |
| Jennifer A. Pietenpol |
| Giuseppe Pizzorno |
| Yves G. Pommier |
| Randy Y.C. Poon |
| Simon N. Powell |
| George C Prendergast |
| Pier Lorenzo Puri |
| Avraham Raz |
| Carrie W. Rinker-Schaeffer |
| Paul D. Robbins |
| Ulrich Rodeck |
| David Ron |
| Ze'ev Ronai |
| Glenn D. Rosen |
| Neal Rosen |
| Pradip Roy-Burman |
| Anil K. Rustgi |
| Konstantin Salnikow |
| Kapaettu Satyamoorthy |
| Axel H. Schonthal |
| Kathleen W. Scotto |
| Ralph A. Scully |
| Said M. Sebti |
| David C. Seldin |
| Arun Seth |
| Prem Seth |
| M. Saeed Sheikh |
| Jonathan W. Simons |
| Keshav K. Singh |
| Kumar Somasundaram |
| Peter J. Stambrook |
| Yi Sun |
| Yoichi Taya |
| Charles Theillet |
| Sam Thiagalingam |
| Michael J. Thirman |
| Andrei Thomas-Tikhonenko |
| Takashi Tokino |
| Philip N. Tsichlis |
| Kristoffer Valerie |
| Kristiina Vuori |
| Valerie M. Weaver |
| Barbara L. Weber |
| Ralph R. Weichselbaum |
| Gen Sheng Wu |
| Yue Xiong |
| Jun Yokota |
| Yoshifumi Yokota |
| Dihua Yu |
| Arthur Zelent |
| Yi-Xin Zeng |
| Qimin Zhan |
| Dong-Er Zhang |
| Wei Zhang |
| Boris Zhivotovsky |
| Bin-Bing Zhou |
| Mary M. Zutter |
|
Editor
contact information |
|
Wafik S. El-Deiry, M.D., Ph.D.
Associate Professor of Medicine
University of Pennsylvania
415 Curie Blvd., CRB 437A
Philadelphia, PA 19104
ph. 215.573.9661
fax. 215.898.0814
email |
|
Associate Editors
contact information
|
|
Avi Ashkenazi, Ph.D.¡ªReceptor Signaling
Genentech, Inc.
Department of Molecular Oncology
1 DNA Way
South San Francisco, CA 94080-4918
ph. 650.225.1853
fax. 650.225.6443 |
|
Joseph R. Bertino, M.D.¡ªMolecular Therapy
Memorial Sloan-Kettering Cancer Center
Molecular Pharmacology and Therapeutics Program
Box No. 8
1275 York Avenue
New York, NY 10021
ph. 212.639.8230
fax. 212.639.2767 |
|
Mikhail V. Blagosklonny, M.D., Ph.D.¡ªSignal Transduction
Brander Cancer Research Institute
New York Medical College
19 Bradhurst Ave
Hawthorne, NY 10532
ph.: 914.347.2801
fax: 914.347.2804 |
|
Carlos Caldas, M.D., F.A.C.P.¡ªCancer Genomics
University of Cambridge, Institute for Medical Researcg
Department of Oncology
Welcome Trust/MRC Building
Addenbrooke's Hospital
Cambridge CB2 2XY
England
ph. 44(1223)33 1989
fax. 44(1223)33 1753 |
|
Lewis A. Chodosh, M.D., Ph.D.¡ªAnimal Models
University of Pennsylvania School of Medicine
Molecular and Cellular Engineering
612 BRB II/III/6160
421 Curie Boulevard
Philadelphia, PA 19104
ph. 215.898.1321
fax. 215.573.6795 |
|
Anindya Dutta, M.D., Ph.D.¡ªDNA Replication
Harvard Medical School
Department of Pathology, Thorn 630
Brigham & Women's Hospital
75 Francis Street
Boston, MA 02115
ph. 617.278.0468
fax. 617.732.7449 |
|
Albert J. Fornace, Jr., M.D.¡ªRadiobiology
National Cancer Institute
Building 37, Room 5C09
Bethesda, MD 20892
ph. 301.402.0744
fax. 301.480.1946 |
|
Douglas Fraker, M.D.¡ªSurgical Oncology
Chief, Surgical Oncology
Hospital of the University of Pennsylvania
University of Pennsylvania School of Medicine
4 Silverstein/4283
3400 Spruce Street
Philadelphia, PA 19104
ph. 215-662-7866 |
|
Alan M. Gewirtz, M.D.¡ªDNA/RNA Therapies
University of Pennsylvania School of Medicine
Room 713 BRB II/III
421 Curie Boulevard
Philadelphia, PA 19104
ph. 215.898.4499
fax. 215.573.2078 |
|
Amato J. Giaccia, Ph.D.¡ªTumor Hypoxia
Stanford University School of Medicine
Department of Radiation Oncology
CBRL, Room GK220
Stanford, CA 94305-5468
ph. 650.723.7366
fax. 650.723.7382 |
|
Antonio Giordano, M.D., Ph.D.¡ªCell Cycle Control
Director, Sbarro Institute for Cancer Research and Molecular Medicine
Professor of Biology and Medicine
College of Science and Technology
Temple University
BioLife Science Bldg. Suite 333
1900 N 12th Street
Philadelphia PA 19122
ph: 215.204.9520
fax: 215.204.9522 |
|
James G. Herman, M.D.¡ªDNA Methylation
Johns Hopkins Cancer Research Building
Room 543
1650 Orleans Street
Baltimore, MD 21231
ph. 410.955.8506
fax. 410.614.9884 |
|
Carl H. June, M.D.¡ªTumor Immunology
Abramson Family Cancer Research Institute
University of Pennsylvania School of Medicine
554 BRB II/III
421 Curie Boulevard
Philadelphia, PA 19104-6160
ph. 215.573.5745
fax. 215.573.8590 |
Scott E. Kern, M.D.¡ªCancer Pathogenesis
Associate Professor
Department of Oncology
451 Cancer Research Building
Johns Hopkins University School of Medicine
1650 Orleans Street
ph. 410.614.3314
fax. 410.614.0671 |
Jonathan Licht, M.D.¡ªTranslocations
Derald H. Ruttenberg Cancer Center
Departments of Medicine and Biochemistry & Molecular Biology
Box 1130
The Mount Sinai School of Medicine
One Gustav Levy Place
New York, NY 10029
ph. 212.659.5487
fax. 212.849.2523 |
Karl Munger, Ph.D.¡ªTumor Virology
Harvard Medical School
Pathology Department and Harvard Center for Cancer
200 Longwood Avenue
Building D2, Room 544A
Boston, MA 02115-5701
ph. 617.432.2878
fax. 617.432.0426 |
Ruth J. Muschel, M.D., Ph.D.¡ªTumor Metastases
Pathology and Laboratory Medicine
Room 269 John Morgan Building
36th & Hamilton Walk
Philadelphia, PA 19104
ph. 215.898.8401
fax. 215.573.4243 |
Ramon E. Parsons, M.D., Ph.D.¡ªHereditary Cancer
Columbia University
Department of Pathology
Room 14-453
630 W. 168th Street
New York, NY 10032
ph. 212.304.7385
fax. 212.304.5511 |
Jeffrey Parvin, M.D., Ph.D.¡ªTranscription/Repair
Harvard Medical School
Brigham & Women's Hospital
75 Francis Street
Boston, MA 02115
ph. 617.278.0818
fax. 617.732.7449 |
Kornelia Polyak, M.D., Ph.D.¡ªCancer Transcriptomes
Department of Adult Oncology
Dana-Farber Cancer Institute
44 Binney St. D740C
Boston, MA 02115
ph. 617.632.2106
fax. 617.632.4005 |
Vivek M. Rangnekar, Ph.D.¡ªResearch Philosophy
University of Kentucky
Department of Radiation Medicine
Combs Cancer Research Building, Room 303
800 Rose Street
Lexington, KY 40536
ph. 606.257.2677
fax. 606.257.9608 |
John C. Reed, M.D., Ph.D.¡ªApoptosis
The Burnham Institute
10901 N. Torrey Pines Road
La Jolla, CA 92037
ph. 858.646.3140
fax. 858.646.3194 |
Jack A. Roth, M.D.¡ªGene Therapy
UT M.D. Anderson Cancer Center
Department of Thoracic & Cardiovascular Surgery
Box 109
1515 Holcombe Boulevard
Houston, TX 77030
ph. 713.792.7664
fax. 713.794.4901 |
Eric K. Rowinsky, M.D.¡ªClinical Trials
Cancer Therapy and Research Center
7th Floor
8122 Datapoint Drive
San Antonio, TX 78229
ph. 210.616.5945
fax. 210.616.5865 |
Saraswati Sukumar, Ph.D.¡ªBreast Biology
Johns Hopkins Oncology Center
Breast Cancer Program
Bunting/Blaustein Building, Room 410
1650 Orleans Street
Baltimore, MD 21231-1000
ph. 410.614.2479
fax. 410.614.4073 |
Robert A. Weinberg, Ph.D.¡ªCancer Biology
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Nine Cambridge Center
Cambridge, MA 02142-1479
ph. 617.258.5159
fax. 617.258.5213 |
Ralph Weissleder, M.D., Ph.D.¡ªTumor Imaging
Harvard Medical School
Massachusetts General Hospital
Boston, MA
ph. 617.726.8226
fax. 617.726.5708 |
|
Bruce Robert Zetter, Ph.D. ¡ªAngiogenesis
Harvard Medical School
Children's Hospital
300 Longwood Avenue
Enders Building, Room 1074
Boston, MA 02115
ph. 617.355.6376
fax. 617.355.7043 |
|
